Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Desano Pharmaceuticals

Gilead Sciences

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity

Sanofi reception

Sanofi launches community health project in China

Partners with local associations to improve chronic disease management

- PMLiVE

GSK signs up for the ‘dawn of cognitive advertising’

Its consumer health arm is among the first to use new IBM offering Watson Ads

China drug medicine pharma prices

Cancer drugs “less affordable in low-income countries”

China and India are among those hit hardest by the rapidly escalating price of therapies

China drug medicine pharma prices

Prices of AZ and GSK drugs slashed in China

GSK says price reductions represent  “defining moment” in improving patient outcomes

- PMLiVE

Chinese regulators restrict Baidu healthcare advertising

Search engine faces clamp down after death of cancer patient

China flag thumb

Chinese biotech claims 90% cure rate for CAR-T therapy

Innovative Cellular Therapeutics presents ‘stellar’ immunotherapy data

- PMLiVE

Gilead bags EU approval for next-generation HIV drug

Descovy expected to replace Truvada as the firm’s lead antiviral blockbuster

- PMLiVE

Gilead boosts liver disease pipeline with $1.2bn acquisition

Also has combination HIV therapy Descovy approved by FDA

- PMLiVE

GSK’s chief executive Sir Andrew Witty to retire next year

The announcement follows months of speculation about his position

Gilead Sciences

Gilead wins US approval for second TAF-based HIV drug

FDA gives Odefsey the green light

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links